Association Between Vascular Adhesion Protein-1 (VAP-1) and MACE in Patients with Coronary Heart Disease: A Cohort Study
DOI: https://doi.org/10.2147/jir.s460605
IF: 4.5
2024-06-05
Journal of Inflammation Research
Abstract:You Zhang, 1, &ast Chi Geng, 1, &ast Yulun Zhou, 1, &ast Feng Li, 1 Siliang Peng, 1 Xinru Guo, 1 Xiaosong Gu, 1 Jing Li, 2 Hui Li 1 1 Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China; 2 Department of Intensive Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hui Li, Department of Cardiology, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Suzhou, 215006, People's Republic of China, Email Jing Li, Department of Intensive Care Medicine, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215006, People's Republic of China, Email Background: Vascular adhesion protein-1 (VAP-1), an inflammation-inducible endothelial cell molecule, was reported to be implicated in a variety of cardiovascular diseases. However, the clinical significance of circulating VAP-1 levels in patients with coronary heart disease (CHD) remains less studied. Patients and Methods: We retrospectively analyzed clinical data of 336 hospitalized patients in the Second Affiliated Hospital of Soochow University from May 2020 to September 2022, 174 of which were diagnosed with CHD. Serum VAP-1 was measured by enzyme-linked immunosorbent assay at enrollment. The primary end point of this study was the occurrence of major adverse cardiovascular events (MACE). The coronary stenosis and clinical manifestations of CHD were assessed and recorded from medical records or follow-up calls. The relevant results were obtained, and the reliability of the conclusions was verified through regression analysis, curve fitting, and survival curve. Results: After adjusting for potential confounders, higher serum VAP-1 level was associated with increased risk of MACE in patients with CHD [(HR = 5.11, 95% CI = 1.02– 25.59), (HR = 5.81, 95% CI = 1.16– 29.11)]. The results of curve fitting and survival analysis were consistent with those of regression analysis. However, no significant association was observed between VAP-1 and MACE in the entire study population [(HR = 5.11, 95% CI = 0.41– 1.93), (HR = 1.17, 95% CI = 0.52– 2.62)]. Furthermore, the level of VAP-1 did not show a significant correlation with coronary stenosis and the clinical manifestations of CHD. Conclusion: These findings suggested that CHD patients with higher serum levels of VAP-1 are at a higher risk of adverse cardiovascular outcomes. Keywords: vascular adhesion protein-1, atherosclerosis, coronary heart disease, major adverse cardiovascular events Coronary heart disease (CHD) is among the leading causes of death worldwide. Atherosclerotic plaque formation and plaque rupture are the main pathogenesis of coronary heart disease. Although current management strategies have demonstrated benefits for patients with CHD, 1,2 there is still a high residual risk after such treatments in both chronic stable coronary artery disease and acute coronary syndrome. A certain proportion of CHD patients will suffer from heart failure, malignant arrhythmia, recurrent myocardial infarction and sudden cardiac death. Therefore, the identification of novel diagnostic and/or prognostic biomarkers for CHD has important clinical significance and may lead to new drug targets for CHD. CHD is characterized by inflammation and fatty deposits in the sub-endothelial space of the coronary arteries. Inflammatory processes play a key role in both the initiation and promotion stages of atherosclerosis, and multiple inflammatory mediators are involved, such as pro-inflammatory cytokines, cell adhesion molecules, acute-phase proteins, complement and autoantibodies. Novel regulators and their diagnostic or therapeutic value for CHD need to be identified to facilitate clinical intervention. 3 Vascular adhesion protein-1 (VAP-1), encoded by the AOC3 (amine oxidase copper-containing 3) gene, is a pro-inflammatory and versatile molecule belonging to semicarbazide-sensitive amine oxidase (SSAO) family. 4,5 VAP-1 is expressed on a variety of cell types (eg, vascular endothelial cells, smooth muscle cells, leukocytes, pericytes, adipocytes and chondrocytes), it can be cleaved from the membrane by matrix metalloproteinase (MMP) and released into the circulation, both the transmembrane form and the soluble form exhibit versatile biological functions. 4 VAP-1 functions as an adhesion molecule, facilitating leukocyte extravasation, thereby promoting inflammation. 6 It is al -Abstract Truncated-
immunology